Page 6 - ஆஂடேரியொ நிறுவனம் க்கு புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Feb 24, 2021   HAMILTON, ON, Feb. 24, 2021 /PRNewswire/ - The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for [ 18F]PSMA-1007. This diagnostic imaging product is a positron-emitting tomography (PET) agent that targets Prostate Specific Membrane Antigen (PSMA), a protein that is overexpressed in prostate cancer. Prostate cancer is the most common malignancy in Canadian men, accounting for over 23,000 new cases per year and 4,000 deaths annually. Men with recurrent or persistent prostate cancer have poor outcomes, and there is an unmet need to accurately define the location and overall spread of disease in this population to help plan effective treatment.

City ofUnited kingdomBruno paquinGlenn baumanLondon health sciences centreMcmaster universityCentre of excellenceNetworks of centres excellenceUr metser division head molecular imagingOntario institute for cancer researchCentre for probe developmentProbe developmentProstate specific membrane antigenJoseph chinWestern universityCancer care